These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 23991948)

  • 1. LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer.
    Han D; Li SJ; Zhu YT; Liu L; Li MX
    Asian Pac J Cancer Prev; 2013; 14(7):4033-9. PubMed ID: 23991948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology.
    Green AS; Chapuis N; Lacombe C; Mayeux P; Bouscary D; Tamburini J
    Cell Cycle; 2011 Jul; 10(13):2115-20. PubMed ID: 21572254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
    Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
    J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Negative regulation of mTOR activity by LKB1-AMPK signaling in non-small cell lung cancer cells.
    Dong LX; Sun LL; Zhang X; Pan L; Lian LJ; Chen Z; Zhong DS
    Acta Pharmacol Sin; 2013 Feb; 34(2):314-8. PubMed ID: 23178462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of E-cadherin/AMPK/mTOR axis in LKB1-induced sensitivity of non-small cell lung cancer to gambogic acid.
    Li X; Tang X; Su J; Xu G; Zhao L; Qi Q
    Biochem Pharmacol; 2019 Nov; 169():113635. PubMed ID: 31513784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
    Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
    Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer.
    Shen X; Zhao Y; Liu G; Zhou HL; Fan J; Zhang L; Li YL; Wang Y; Liang J; Xu ZX
    Life Sci; 2020 Sep; 256():117923. PubMed ID: 32522567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
    Han S; Khuri FR; Roman J
    Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.
    Xiao P; Sun LL; Wang J; Han RL; Ma Q; Zhong DS
    Acta Pharmacol Sin; 2015 Sep; 36(9):1107-12. PubMed ID: 26027660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mTOR pathway in lung cancer and implications for therapy and biomarker analysis.
    Ekman S; Wynes MW; Hirsch FR
    J Thorac Oncol; 2012 Jun; 7(6):947-53. PubMed ID: 22588151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner.
    Meng J; Majidi M; Fang B; Ji L; Bekele BN; Minna JD; Roth JA
    PLoS One; 2013; 8(10):e77067. PubMed ID: 24146957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
    Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
    Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
    Sun Z; Wang Z; Liu X; Wang D
    Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting LKB1 signaling in cancer.
    Korsse SE; Peppelenbosch MP; van Veelen W
    Biochim Biophys Acta; 2013 Apr; 1835(2):194-210. PubMed ID: 23287572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor.
    Liu JL; Mao Z; Gallick GE; Yung WK
    Neuro Oncol; 2011 Feb; 13(2):184-94. PubMed ID: 21123367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
    Fumarola C; Bonelli MA; Petronini PG; Alfieri RR
    Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition.
    Mahoney CL; Choudhury B; Davies H; Edkins S; Greenman C; Haaften Gv; Mironenko T; Santarius T; Stevens C; Stratton MR; Futreal PA
    Br J Cancer; 2009 Jan; 100(2):370-5. PubMed ID: 19165201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC.
    Hollstein PE; Eichner LJ; Brun SN; Kamireddy A; Svensson RU; Vera LI; Ross DS; Rymoff TJ; Hutchins A; Galvez HM; Williams AE; Shokhirev MN; Screaton RA; Berdeaux R; Shaw RJ
    Cancer Discov; 2019 Nov; 9(11):1606-1627. PubMed ID: 31350328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CO suppresses prostate cancer cell growth by directly targeting LKB1/AMPK/mTOR pathway in vitro and in vivo.
    Yan Y; Du C; Li G; Chen L; Yan Y; Chen G; Hu W; Chang L
    Urol Oncol; 2018 Jun; 36(6):312.e1-312.e8. PubMed ID: 29566977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Tumor Activity of Yuanhuacine by Regulating AMPK/mTOR Signaling Pathway and Actin Cytoskeleton Organization in Non-Small Cell Lung Cancer Cells.
    Kang JI; Hong JY; Lee HJ; Bae SY; Jung C; Park HJ; Lee SK
    PLoS One; 2015; 10(12):e0144368. PubMed ID: 26656173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.